Peptide

A peptide comprises amino acid residues joined through peptide bonds.

A peptide linker is a peptide segment connecting protein components within one continuous polypeptide chain. It joins their backbones while allowing relative positioning that depends on the segment's sequence and conformation. The connected regions can be distinct protein domains or components brought together in a fusion protein.

For an original residue-accounting example, components of 180 and 240 amino acid residues joined by a six-residue peptide linker produce a chain of 426 residues. Replacing that connector with an eighteen-residue peptide linker produces 438 residues. The twelve-residue difference specifies a sequence-length change; it does not uniquely determine the end-to-end distance of a polymer chain, binding affinity or catalytic rate.

A structural experiment illustrates why the distinction matters. Researchers tethered adrenodoxin to the cholesterol side-chain cleavage enzyme through different peptide linkers. The resulting crystallizable fusion proteins captured a similar interface, yet their catalytic activities differed from the nonfused comparison, and electron transfer depended on linker length even when substrate affinity was preserved.^[ref]

Linker choice is therefore part of the experiment. Structural capture, substrate recognition and catalytic performance are separate readouts. Success at one of them does not establish that the connector reproduces every property of the freely associating components.

Peptide sequencing determines the order of amino acid residues in a peptide, conventionally read from its N-terminus toward its C-terminus. This is more information than amino acid composition: AGST and TSAG contain the same four residues but put different neighbours together.

Overlapping fragments make the distinction concrete. If two oriented fragments from one chain are AGS and GST, their shared GS segment supports the combined sequence AGST. This is a toy reconstruction, assuming the fragments overlap and repeated segments do not create ambiguity. A composition measurement alone cannot supply that order.

Sequencing can also locate a chemically identified site inside a protein. In a 1990 1-aminocyclopropane-1-carboxylate synthase experiment, a labelled active-site segment was isolated after protein digestion. Sequence analysis placed a lysine within it, while chemical analysis linked that residue to pyridoxal phosphate. The combination connected an ordered segment to a chemical function rather than merely listing the sample's amino acids.^[ref]

A cyclic peptide contains a covalently closed ring incorporating part or all of its amino acid residue chain. A head-to-tail ring joins the usual terminal amino and carboxyl groups through a peptide bond. Other ring architectures involve side chains or different linkages, so the positions and chemical types of the closures must be specified.^[ref]

For a topology example, a linear unbranched chain of six amino acid residues has five backbone peptide bonds. Closing that chain head-to-tail adds a sixth bond and removes its free N-terminus and C-terminus. It preserves the residue order around the ring, although choosing a different residue as the written starting point does not create a new ring. This counting example does not imply that every chosen sequence readily forms such a ring.

Alpha-amanitin supplies a biological example: it combines a cyclic eight-residue framework with an additional sulfur-containing bridge. Its shape is therefore more constrained than residue count alone reveals.^[ref] Ring closure changes accessible conformations; its effects on stability, binding and biological activity depend on the particular peptide and its surroundings.

A fibrinopeptide is a short peptide released from fibrinogen during its proteolytic conversion toward fibrin. The principal forms are Fibrinopeptide A and Fibrinopeptide B, cleaved from the amino-terminal regions of the A-alpha and B-beta chains, respectively. Their removal exposes molecular sites that promote fibrin assembly.^[ref]

Experiments measured the release of the two fibrinopeptides separately and related their kinetics to fibrin polymerization. Under the tested solution conditions, release of Fibrinopeptide A preceded the main release of Fibrinopeptide B, with assembly affecting the later step.^[ref]

The small released fragments and the remaining network-forming material have different roles. For a stipulated counting example, if each converted fibrinogen molecule releases two copies of one fibrinopeptide, converting 3 nmol generates 6 nmol of that fragment. The amount recovered can report the extent of cleavage; it does not by itself determine the final clot's stiffness or network geometry.

Fibrinopeptide B is the 14-amino acid peptide that thrombin releases from the N-terminus of each B-beta chain of human fibrinogen. Cleavage exposes the B knob on the remaining fibrin molecule, allowing a fibrin knob-hole interaction. Each fibrinogen molecule contains two B-beta chains and can therefore release two copies of Fibrinopeptide B.^[ref]

Its release need not track Fibrinopeptide A release identically. A study comparing dissolved and surface-adsorbed fibrinogen incubated the preparations with thrombin and measured the released peptides by high-performance liquid chromatography. Surface-bound preparations released Fibrinopeptide B without the characteristic solution-phase lag; densely adsorbed preparations could release more Fibrinopeptide B than Fibrinopeptide A.^[ref]

The experiment shows why a measured fibrinopeptide ratio needs its reaction conditions. Molecular presentation at a surface changes access to cleavage sites, so a typical sequence observed in solution should not be turned into an unconditional rule for every preparation.

Fibrinopeptide A is the 16-amino acid peptide released from the N-terminus of each A-alpha chain of human fibrinogen by thrombin. Removing Fibrinopeptide A exposes the A knob on the remaining molecule, enabling a fibrin knob-hole interaction. The released fragment and the exposed binding site are different objects.^[ref]

Release of Fibrinopeptide A provides a measurable record of a particular peptide bond cleavage. A kinetic study measured Fibrinopeptide A and Fibrinopeptide B separately: under its solution conditions, at least 97% of Fibrinopeptide B release followed Fibrinopeptide A release. The study also found that a change at the cleavage-site arginine strongly reduced catalytic efficiency, linking amino acid identity to reaction rate.^[ref]

For a counting example, $1\mathrm{nmol}$ of fully cleaved fibrinogen yields $2\mathrm{nmol}$ of Fibrinopeptide A, because each molecule has two A-alpha chains. Partial cleavage gives less; this stoichiometric upper limit does not specify the final fibrin network's geometry.

Alpha-amanitin is a mushroom-derived cyclic peptide containing eight amino acid residues. It inhibits RNA polymerase II, making it a molecular tool for studying transcription as well as a naturally occurring toxin. Its small residue count coexists with a constrained ring-and-bridge chemical structure.^[ref]

A structural experiment soaked RNA polymerase II transcription elongation complex crystals with alpha-amanitin. The inhibitor trapped a state resolved at $3.4\text{A˚}$ in which the entering DNA base lay above a shifted RNA polymerase bridge helix instead of occupying the normal templating position. The authors interpreted this as a possible intermediate in the polymerase's movement along DNA.^[ref]

This illustrates how blocking a moving enzyme can reveal part of its reaction cycle. A trapped structure identifies a physically accessible arrangement; establishing how frequently that arrangement occurs during uninhibited transcription requires kinetic evidence as well. Inhibition of RNA polymerase II should also be specified by assay conditions rather than treated as a universal claim about every RNA polymerase.^[ref]

A tripeptide contains three amino acid residues linked by peptide bonds. Even three residues have an order: Gly-Ala-Ser and Ser-Ala-Gly have the same residue composition but different sequences and terminal environments. Short length does not imply biological inactivity, since small peptides can participate in signalling or chemical protection. Covalent modifications and nonstandard linkages require specification beyond the simple residue count. ^[ref]